Enhanced antitumor efficacy of bispecific antibody blocking PD-L1 and LAG-3 with doxorubicin: mechanism and safety evaluation. Zhang C, Liu J, Gu T, Meng X, et al. Breast Cancer Res Treat 2025;211:637-648.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Zhang C, Liu J, Gu T, Meng X, et al. Enhanced antitumor efficacy of bispecific antibody blocking PD-L1 and LAG-3 with doxorubicin: mechanism and safety evaluation. Breast Cancer Res Treat 2025;211:637-648.
PMID: 40050525